Biophytis S.A. (BPTS): history, ownership, mission, how it works & makes money

A Brief History of Biophytis S.A. (BPTS)

Foundation and Early Developments

Biophytis S.A., a biopharmaceutical company, was founded in 2009 in France. The firm specializes in the development of therapies for age-related diseases and conditions. The company's primary focus has been on the treatment of sarcopenia and other degenerative disorders.

Initial Public Offering (IPO)

In 2019, Biophytis went public on the Euronext Growth Paris stock exchange. The IPO raised approximately €12 million, providing necessary funding for the development of its leading drug candidates.

Key Products and Pipeline

Biophytis' lead product is Sarconeos (BIO101), which targets sarcopenia, a condition characterized by loss of muscle mass and strength. As of 2023, BIO101 is undergoing multiple Phase 2 clinical trials. The anticipated market for sarcopenia management is projected to reach $90 billion by 2030.

Financial Performance

As of the end of Q1 2023, Biophytis reported a total revenue of €1.5 million, representing a growth of 10% from the previous fiscal year. The company's total assets were valued at €25 million, while liabilities stood at €6 million, leading to a net equity of €19 million.

Recent Developments

In early 2023, Biophytis secured €5 million in funding through a private placement to accelerate the development of its clinical pipeline. The company plans to initiate a Phase 2 trial for Sarconeos in the second half of 2023 and is collaborating with various research institutions to enhance its development capabilities.

Market Environment

The global market for sarcopenia treatment is evolving rapidly. With an increase in aging populations, the demand for nutritional and therapeutic interventions is expected to rise significantly. Biophytis aims to position itself at the forefront of this market.

• Projected sarcopenia market growth: 8% CAGR until 2030
• Key competitors include:
  • Myos Rens Technology
  • Novartis
  • Pfizer

Future Outlook

Biophytis is focused on advancing its drug candidates through clinical trials while exploring additional partnerships for commercialization. The company is optimistic about the potential of its products in addressing unmet needs in the aging population.

A Who Owns Biophytis S.A. (BPTS)

Current Ownership Structure

As of the latest data available, Biophytis S.A. (BPTS) has a diversified ownership structure comprising institutional investors, private shareholders, and company executives. The following table outlines the major shareholders in the company.

Recent Shareholder Changes

In Q3 2023, Biophytis saw some notable changes in its shareholder base:

• Fonds Stratégique de Participations increased its holdings by 2.0%.
• Investissement Quebec slightly reduced its stake by 1.2%.
• The public float expanded due to a secondary offering.

Financial Overview

The market capitalization of Biophytis S.A. as of October 2023 stands at approximately €45 million, reflecting its share price of €6.50. The company has experienced fluctuations in its stock price, which has been influenced by recent clinical trial results.

Market Dynamics

Biophytis operates in the biotechnology sector focused on aging-related diseases and has been actively pursuing partnerships. Its financial performance illustrates the volatility typical of biotech firms, with a burn rate estimated at €3 million per quarter.

Future Outlook

Biophytis is actively seeking to expand its funding options and is in discussions for potential collaborations to bolster its financial standing. The outlook entails a strategic focus on clinical development, which may attract further institutional investments in the near future.

Conclusion on Ownership Trends

The ownership of Biophytis S.A. presents a mixed landscape, with significant institutional interest. The fluctuation in shareholder stakes and the ongoing financial developments indicate a dynamic ownership structure, crucial for the company’s growth trajectory.

Biophytis S.A. (BPTS) Mission Statement

Company Overview

Biophytis S.A. (BPTS) is a publicly traded biotechnology company focused on developing innovative therapies for age-related diseases. Founded in 2005, the company is listed on Euronext Paris and aims to address significant unmet medical needs through its research and development efforts.

Core Mission and Vision

The mission of Biophytis is to bring to market treatments that improve the quality of life and prolong the lifespan of patients with age-related conditions, particularly in conditions such as sarcopenia and respiratory diseases.

Strategic Objectives

• To develop therapies that address the biological mechanisms of aging.
• To conduct clinical trials that demonstrate the efficacy and safety of its products.
• To establish partnerships with pharmaceutical companies for broader market access.

Financial Overview

As of October 2023, Biophytis S.A. reported the following financial statistics:

Product Pipeline

Biophytis is advancing several clinical programs, notably:

• Sarconeos (BIO101): Targeting sarcopenia, currently in Phase 2 clinical trials.
• SARCO-AGE: A clinical trial assessing the efficacy of BIO101 in older adults.
• COVID-19 Treatment: Investigating the potential application of its therapies in COVID-19 related complications.

Regulatory Milestones

Biophytis has achieved several key regulatory milestones:

• FDA Orphan Drug Designation for BIO101.
• EMA's Orphan Medicinal Product designation for sarcopenia.
• Successful completion of initial Phase 1 studies.

Partnerships and Collaborations

Biophytis has established various partnerships aimed at enhancing its research capabilities:

• Collaboration with academic institutions for clinical research.
• Partnerships with other biotech firms to co-develop therapies.

Outlook and Future Directions

The company is focused on advancing its clinical trials and expanding its therapeutic offerings. By 2025, Biophytis aims to have its lead product, BIO101, move into Phase 3 trials.

How Biophytis S.A. (BPTS) Works

Overview of Biophytis S.A.

Biophytis S.A., listed on the Euronext Paris under the ticker BPTS, is a biopharmaceutical company focused on developing treatments for age-related diseases and conditions. The company's primary mission is to leverage its expertise in biology and medicinal chemistry to create therapies that address unmet medical needs in the elderly population.

Financial Performance

As of September 30, 2023, Biophytis reported the following financial data:

Key Products and Pipeline

Biophytis has several key products in various stages of development:

• BSF 200: A product aimed at treating sarcopenia.
• BSF 300: Targeted for the treatment of COVID-19 related symptoms in patients with comorbidities.
• Clinical Trials: Biophytis has ongoing Phase 2 clinical trials for BSF 200.

Research and Development Focus

The company focuses on the following areas in its research and development:

• Age-related sarcopenia and frailty.
• Respiratory diseases, particularly in the context of COVID-19.
• Innovative formulations and delivery methods for drug administration.

Collaborations and Partnerships

Biophytis has engaged in various collaborations to enhance its research capabilities:

• Partnership with academic institutions for clinical trials.
• Alliances with contract research organizations (CROs) for drug development.
• Collaboration with regulatory agencies for streamlined approval processes.

Regulatory Milestones

Biophytis has achieved several regulatory milestones:

Market Position and Competition

Biophytis operates in a competitive landscape characterized by key players such as:

• Pfizer Inc.
• Novartis AG
• Regeneron Pharmaceuticals
• AstraZeneca PLC

Stock Performance

The stock performance of Biophytis S.A. (BPTS) shows:

Future Prospects

The company is optimistic about future growth, particularly through:

• Successful completion of clinical trials.
• Potential partnerships with larger pharmaceutical firms.
• Expansion into new therapeutic areas.

How Biophytis S.A. (BPTS) Makes Money

Revenue Streams

Biophytis S.A. generates revenue primarily through the development and commercialization of therapeutic products aimed at addressing age-related diseases and conditions. Key areas of focus include:

• Clinical development of drug candidates
• Partnerships and collaborations with pharmaceutical companies
• Grants and funding from research organizations

Clinical Development of Drug Candidates

Biophytis is focused on the clinical development of its drug candidates, notably:

• Sarconeos (BIO101): Targeting sarcopenia (age-related muscle loss)
• Sarconeos (BIO101): Expected to reach the market around 2024 with projected sales of €500 million annually in Europe.

Partnerships and Collaborations

The company engages in strategic partnerships that enhance its financial stability:

• Collaboration with pharmaceutical firms: These partnerships may include upfront payments, milestone payments, and royalties on future sales.
• Recent partnership deals: Notable collaborations with institutions such as INRIA (National Institute for Research in Computer Science and Automation).

Grants and Funding

Biophytis S.A. secures funding through grants and public financing:

• Public subsidies received in 2022: €1.3 million from French public funds for research
• European Union funding for research projects: Approximately €800,000 awarded in 2023 for specific studies.

Financial Performance Metrics

Key financial metrics showcasing Biophytis's economic position are as follows:

Market Opportunities

Biophytis targets lucrative markets with significant growth potential:

• Global Sarcopenia Treatment Market: Estimated to reach €1 billion by 2028.
• Age-related disease market growth: Expected CAGR of 7.5% from 2023 to 2030.

Investment and Shareholder Value

Biophytis S.A. attracts investors through its promising pipeline:

• Stock performance as of October 2023: Share price around €1.10, with a market capitalization of €25 million.
• Investments raised in recent funding rounds: €5 million secured in equity financing in early 2023.